ADVERTISEMENT
  • News
  • New York
  • Technology
  • Culture
  • Entertainment
  • Sport
  • More
    • Politics
    • Lifestyle
    • TV
    • Games
Tuesday, June 17, 2025
  • Login
No Result
View All Result
NEWSLETTER
FINCHANNEL
  • Home
  • Business
    • BANKS
      • GeoBanks
    • Finance
    • Insurance
    • Markets
    • Pharmacy
    • Press Releases
    • RealEstate
    • RealEstate
    • Finance
    • Insurance
    • Banks
      • GeoBanks
    • Markets
    • Press Releases
    • Personal Finance
  • World
    • Americas
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Americas
    • UK local news
  • Travel
    • Hotels in Georgia
    • Tours in Georgia
  • Videos
    • Promos
    • Soundslides
    • TheClinics
    • TheHoteliers
    • TheUniversities
    • TheHoteliers
    • TheClinics
    • TheUniversities
    • BestWorkplaces
    • Soundslides
    • Promos
    • Banking Forum
      • Promos
      • Soundslides
      • TheClinics
      • TheHoteliers
      • TheUniversities
  • Opinion
    • Editorial
      • Analysis
      • GORBI
      • OP-ED
      • VISA Editorial
    • Analysis
    • Gorbi
    • Book reviews
  • Tech
  • Interview
  • People
    • lifestyle
    • Health & Beauty
      • Coronavirus
    • LifeStyle
    • Employment
      • MyCareer
    • Education
    • Media
    • Celebrities
  • Oil&Auto
    • Auto
    • Energy
  • EN
    • EN
    • GE
  • Home
  • Business
    • BANKS
      • GeoBanks
    • Finance
    • Insurance
    • Markets
    • Pharmacy
    • Press Releases
    • RealEstate
    • RealEstate
    • Finance
    • Insurance
    • Banks
      • GeoBanks
    • Markets
    • Press Releases
    • Personal Finance
  • World
    • Americas
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Americas
    • UK local news
  • Travel
    • Hotels in Georgia
    • Tours in Georgia
  • Videos
    • Promos
    • Soundslides
    • TheClinics
    • TheHoteliers
    • TheUniversities
    • TheHoteliers
    • TheClinics
    • TheUniversities
    • BestWorkplaces
    • Soundslides
    • Promos
    • Banking Forum
      • Promos
      • Soundslides
      • TheClinics
      • TheHoteliers
      • TheUniversities
  • Opinion
    • Editorial
      • Analysis
      • GORBI
      • OP-ED
      • VISA Editorial
    • Analysis
    • Gorbi
    • Book reviews
  • Tech
  • Interview
  • People
    • lifestyle
    • Health & Beauty
      • Coronavirus
    • LifeStyle
    • Employment
      • MyCareer
    • Education
    • Media
    • Celebrities
  • Oil&Auto
    • Auto
    • Energy
  • EN
    • EN
    • GE
No Result
View All Result
FINCHANNEL
No Result
View All Result
Home Business Pharmacy

Gilead Announces 2-Year Data from Pivotal Phase III Studies Evaluating Viread(R) for Chronic Hepatit

The FINANCIAL by The FINANCIAL
November 3, 2008
in Pharmacy
Reading Time: 3 mins read
7
A A
0
Share on FacebookShare on Twitter

The FINANCIAL — Gilead Sciences, Inc. (Nasdaq:GILD) on November 1 announced the presentation of two-year (96-week) data from two Phase III pivotal clinical trials, Studies 102 and 103, evaluating the safety and efficacy of once-daily Viread(R) (tenofovir disoproxil fumarate) among adult patients with chronic hepatitis B virus (HBV) infection.

 

These data will be presented during oral sessions at the annual meeting of the American Association for the Study of Liver Diseases (The Liver Meeting 2008) being held this week in San Francisco (October 31-November 4).

RelatedPosts

A Closer Look at Bioactive Peptides and Their Impact on Health

Roche ranked the most sustainable healthcare company in the DJSI

Gilead and Novo Nordisk announced new data from proof-of-concept trial in NASH

Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund

 

Studies 102 and 103 will evaluate treatment with Viread for up to eight years among patients with HBeAg-negative and HBeAg-positive chronic hepatitis B, respectively, with compensated liver disease. Patients in both studies were originally randomized to receive Viread or Hepsera(R) (adefovir dipivoxil). After the completion of 48 weeks of randomized blinded therapy, all eligible patients were rolled over to open-label Viread monotherapy.

 

According to Gilead, these new data show that patients who received Viread for up to 96 weeks experienced sustained suppression of HBV levels in the blood (91 percent and 78 percent for Studies 102 and 103, respectively). The studies also show that all Hepsera-treated patients whose HBV levels were suppressed at week 48 maintained viral suppression after rolling over to Viread, while Hepsera-treated patients with HBV DNA levels above 400 copies/mL at week 48 experienced significant viral suppression after rolling over to Viread. Additionally, by week 96 of Study 103, 6 percent of all patients continuing treatment in both groups experienced "s" antigen (HBsAg) loss, which contributes to resolution of chronic hepatitis B infection (HBsAg seroconversion rates were 4 percent among patients originally randomized to receive Viread and 5 percent for patients who rolled over from Hepsera).

 

Notably, no mutations associated with resistance to Viread were reported among patients receiving Viread monotherapy for up to 96 weeks or in Hepsera-treated patients who rolled over to Viread.

 

"In this study, Viread produced a significant and sustained effect over two years of treatment with no evidence of resistance, which is a substantial clinical finding," said Patrick Marcellin, MD of Hopital Beaujon in Clichy, France, the principal investigator of Study 102. "Additionally, patients in this study taking Hepsera were rolled over to Viread without new safety signals and without compromising the efficacy of anti-HBV treatment."

 

The U.S. Food and Drug Administration (FDA) approved Viread for chronic HBV in adults in August 2008 based on earlier (48-week) results from these studies. Viread and Hepsera are both manufactured by Gilead.

 

"One of the most important considerations in treating chronic hepatitis B is resistance. It is reassuring to see that no patients from either arm of the study demonstrated resistance to Viread at 96 weeks of treatment," said Jenny Heathcote, MD of the University of Toronto, Canada, the principal investigator for Study 103. "It is also notable that 6 percent of HBeAg-positive patients experienced "s" antigen loss."

 

Chronic HBV affects an estimated 400 million people worldwide, including two million people in the United States. Many are unaware that they are infected because the disease may not produce obvious symptoms.

 

One in four people with chronic hepatitis B die from complications such as cirrhosis and liver cancer. In the United States, Asian Americans are disproportionately affected: Foreign-born Asians are 100 times more likely to have the disease compared to non-Asians in the U.S. population. In September 2008, partly in response to advances in HBV therapy, the U.S. Centers for Disease Control and Prevention (CDC) published new HBV screening guidelines recommending that all individuals from Asian countries be tested for the disease.

 

In addition to its indication for HBV, Viread is also indicated in combination with other antiretroviral agents for the treatment of HIV infection in adults, and is currently the most-prescribed molecule in antiretroviral therapy in the United States.

 

 

Related Posts

A Closer Look at Bioactive Peptides and Their Impact on Health
Clinics

A Closer Look at Bioactive Peptides and Their Impact on Health

by Accessily
October 15, 2024
0

Introduction to Bioactive Peptides What are Bioactive Peptides? Bioactive peptides are short protein fragments, typically ranging from 2 to 20...

Read more
Roche ranked the most sustainable healthcare company in the DJSI

Roche ranked the most sustainable healthcare company in the DJSI

November 16, 2020
Gilead and Novo Nordisk announced new data from proof-of-concept trial in NASH

Gilead and Novo Nordisk announced new data from proof-of-concept trial in NASH

November 16, 2020
Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund

Metagenomi closes USD 65 million Series A financing led by Leaps by Bayer and Humboldt Fund

November 12, 2020

Discussion about this post

  • Trending
  • Comments
  • Latest
Ampersand wins £22m five-year contract at London Zoo

Ampersand wins £22m five-year contract at London Zoo

June 25, 2012
Goga Samushia, Director of Commersant

Commersant to Launch New Multimedia Finance Project

June 14, 2025
Fullscript vs. Rupa Health: What the Acquisition Means for Providers and Patients

Fullscript vs. Rupa Health: What the Acquisition Means for Providers and Patients

June 11, 2025
Will digital media be decisive in general election – as it was in Donald Trump’s victory? 

How to Align Social Media with Your Overall Marketing Strategy

June 11, 2025
Leon Botstein’s Five-Decade Transformation at Bard College

Leon Botstein’s Five-Decade Transformation at Bard College

May 28, 2025
Looking For A New Property? Here Are 10 Things You Need To Consider During The Hunt

Looking For A New Property? Here Are 10 Things You Need To Consider During The Hunt

June 16, 2025
7 Digital Marketing Techniques for Business Owners in 2020

Lockton Surprasses $4 Billion in FY2025 revenue

June 16, 2025
Protected: Why Insurance is So Important for Project Management

Protected: Why Insurance is So Important for Project Management

June 16, 2025
Mounting pressure beginning to drive progress for women in senior leadership

Women-Led Businesses Continue To Grow in 2025

June 16, 2025
Ukraine fires US-supplied longer-range missiles into Russia, Moscow says

Ukraine Support: Europe largely fills the US aid withdrawal, lead by the Nordics and the UK

June 16, 2025
ADVERTISEMENT

Popular Last 24h

  • Goga Samushia, Director of Commersant

    Commersant to Launch New Multimedia Finance Project

    59 shares
    Share 24 Tweet 15
  • Women-Led Businesses Continue To Grow in 2025

    28 shares
    Share 11 Tweet 7
  • Ukraine Support: Europe largely fills the US aid withdrawal, lead by the Nordics and the UK

    22 shares
    Share 9 Tweet 6
  • Ampersand wins £22m five-year contract at London Zoo

    3631 shares
    Share 1452 Tweet 908
  • Leon Botstein’s Five-Decade Transformation at Bard College

    315 shares
    Share 126 Tweet 79
  • Nestlé Georgia: A Leader in Baby Food Quality and Innovation

    39 shares
    Share 16 Tweet 10
  • New Columns and Global Partnerships on the Horizon for Publika

    23 shares
    Share 9 Tweet 6

LATEST POSTS

Looking For A New Property? Here Are 10 Things You Need To Consider During The Hunt

Looking For A New Property? Here Are 10 Things You Need To Consider During The Hunt

June 16, 2025
7 Digital Marketing Techniques for Business Owners in 2020

Lockton Surprasses $4 Billion in FY2025 revenue

June 16, 2025
Protected: Why Insurance is So Important for Project Management

Protected: Why Insurance is So Important for Project Management

June 16, 2025
Mounting pressure beginning to drive progress for women in senior leadership

Women-Led Businesses Continue To Grow in 2025

June 16, 2025
Ukraine fires US-supplied longer-range missiles into Russia, Moscow says

Ukraine Support: Europe largely fills the US aid withdrawal, lead by the Nordics and the UK

June 16, 2025
Supply chain management degree course among best in world

 How Apps Are Reshaping Supplier Risk and Compliance

June 15, 2025

A Tutorial on Crafting the Perfect LinkedIn Profile Along with Your Resume

June 15, 2025
Israel’s Illegal, Counterproductive Attacks Make a Nuclear-Armed Iran More Likely

Israel’s Illegal, Counterproductive Attacks Make a Nuclear-Armed Iran More Likely

June 15, 2025
REVAZ NATROSHVILI, CEO of Proservice

Proservice Launches Cloud Solutions, Expanding Infrastructure with Innovations

June 14, 2025
ROLAND ERADZE, Founder of Bona Georgia

Bona Georgia Expands with New Showroom and Innovations in Floor Care

June 14, 2025

LATESTBUSINESS

7 Digital Marketing Techniques for Business Owners in 2020

Lockton Surprasses $4 Billion in FY2025 revenue

by The FINANCIAL
June 16, 2025
0

Mounting pressure beginning to drive progress for women in senior leadership

Women-Led Businesses Continue To Grow in 2025

by The FINANCIAL
June 16, 2025
0

REVAZ NATROSHVILI, CEO of Proservice

Proservice Launches Cloud Solutions, Expanding Infrastructure with Innovations

by Golden Brand
June 14, 2025
0

ROLAND ERADZE, Founder of Bona Georgia

Bona Georgia Expands with New Showroom and Innovations in Floor Care

by Golden Brand
June 14, 2025
0

Foodmg

The Standard of Excellence in Catering: Food Management Group Wins Golden Brand Award

by Golden Brand
June 14, 2025
0

RMN02917_sante004_prevs

From France to Georgia: Président Cheese Wins the Golden Brand Award

by Golden Brand
June 14, 2025
0

TAMTA KALANDADZE, Brand Manager at BMS

Pasta Reggia Expands Its Footprint in Georgian Market with New Products

by Golden Brand
June 14, 2025
0

EKA MAGHLAPERIDZE, Head of the Marketing Department at Libo Group

Fino: A Fresh Presence in the Georgian Market

by Golden Brand
June 14, 2025
0

GET IN TOUCH

Submit guest post/Letters to the Editor:

editor (at) finchannel.com

Sales & Marketing: (+995 558) 03 03 03 Email: marketing (at) finchannel.com

Whatsup: (+995 599) 96 52 52

Georgia:

(+995 599) 96 52 52 Email: editor (@) finchannel.com

Postal address: 17 Mtskheta str. Tbilisi, Georgia 0179 The FINANCIAL

RESOURCE

  • Work at the FINANCIAL
  • ePaper
  • Advertise in The FINANCIAL
  • Access ePaper
  • Guest posts
  • Contributed articles
  • AmericanStockNews
  • Coupon Codes
  • GLOSSY MAG
American Culture Center
ACC Partner

GUIDEBOOK

  • Meet our team
  • Invest in Georgia
  • Become contributor
  • Archive

FOLLOW US

  • Facebook
  • Twitter
  • Google+
  • Youtube
No Result
View All Result
  • Home
  • Business
    • BANKS
      • GeoBanks
    • Finance
    • Insurance
    • Markets
    • Pharmacy
    • Press Releases
    • RealEstate
    • RealEstate
    • Finance
    • Insurance
    • Banks
      • GeoBanks
    • Markets
    • Press Releases
    • Personal Finance
  • World
    • Americas
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Europe
    • Georgia
      • Media
    • Ukraine
    • Americas
    • UK local news
  • Travel
    • Hotels in Georgia
    • Tours in Georgia
  • Videos
    • Promos
    • Soundslides
    • TheClinics
    • TheHoteliers
    • TheUniversities
    • TheHoteliers
    • TheClinics
    • TheUniversities
    • BestWorkplaces
    • Soundslides
    • Promos
    • Banking Forum
      • Promos
      • Soundslides
      • TheClinics
      • TheHoteliers
      • TheUniversities
  • Opinion
    • Editorial
      • Analysis
      • GORBI
      • OP-ED
      • VISA Editorial
    • Analysis
    • Gorbi
    • Book reviews
  • Tech
  • Interview
  • People
    • lifestyle
    • Health & Beauty
      • Coronavirus
    • LifeStyle
    • Employment
      • MyCareer
    • Education
    • Media
    • Celebrities
  • Oil&Auto
    • Auto
    • Energy
  • EN
    • EN
    • GE

© 2025 Intelligence Group llc

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.